TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00175383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteinizing hormone-releasing hormone (LHRH) short acting or long acting
Description: See Detailed Description.
Study: NCT02080533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow-paced respiration therapy
Description: The FDA-approved RESPeRATE device contains headphones and a sensor that attaches to the chest to detect inhalation and exhalation. Musical tones synchronize with the respiratory cycle to slowly guide the user to decrease respirations.
Study: NCT04063618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy
Description: The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles, joints, and tissues are moved using techniques that include stretching, gentle pressure, and resistance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Concussion Treatment
Description: Standard of care for concussion management is cognitive rest, meaning no stimulation (or as little as possible). This mean no TV/phones/music/school/homework generally for 24 hours. After that a return to academic work is typically started. Once patient is symptom free for 24 hours, then the return to play protocol is initiated (this takes 7 total days to complete at a minimum).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Concussion Treatment
Description: Standard of care for concussion management is cognitive rest, meaning no stimulation (or as little as possible). This mean no TV/phones/music/school/homework generally for 24 hours. After that a return to academic work is typically started. Once patient is symptom free for 24 hours, then the return to play protocol is initiated (this takes 7 total days to complete at a minimum).
Study: NCT01325857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block
Description: Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Procedure: Bilateral superficial cervical plexus block with normal saline 20ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
Study: NCT00819858

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF (Plumpynut®)
Description: Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
Study: NCT03860571

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-11
Description: Oral tablet
Study: NCT02746029

Intervention type: OTHER
Intervention: Clinical examination
Study: NCT03969784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw, tumoral biopsy tissus
Description: Patient will have specific blood draw and part of their tumoral tissu biopsied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood draw, tumoral biopsy tissus
Description: Patient will have specific blood draw and part of their tumoral tissu biopsied
Study: NCT04581031

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous vital sign monitoring - Isansys Patient Status Engine
Description: CE marked wearable continuous vital signs monitors

Intervention type: OTHER
Group type: OTHER
Intervention: Machine Learning/AI Algorithm
Description: Patient data will be subjected to machine learning/AI algorithms to determine whether algorithms may be beneficial as an early indication of patient's condition worsening.
Study: NCT00123058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse administered
Description: Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse administered
Description: Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BP Monitor
Description: Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BP Monitor
Description: Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.
Study: NCT04071366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune effector cell therapy
Description: Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo twice daily.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yescarta
Description: Eligible participants are receiving Yescarta (An infusion of chimeric antigen receptor (CAR)-transduced autologous T cells) for relapsed or refractory larbe B-cell lymphoma or follicular lymphoma intravenously.
Study: NCT04449679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Monitoring System
Description: Receive RT-CAMSS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation
Description: Receive tailored feedback, including consultation with nurse
Study: NCT03521544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-myofascial release
Description: The subjects roll a foam roller under a determinated part of the body to self-massage that area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-myofascial release
Description: The subjects roll a foam roller under a determinated part of the body to self-massage that area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-myofascial release
Description: The subjects roll a foam roller under a determinated part of the body to self-massage that area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-myofascial release
Description: The subjects roll a foam roller under a determinated part of the body to self-massage that area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-myofascial release
Description: The subjects roll a foam roller under a determinated part of the body to self-massage that area.
Study: NCT01353105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex vivo lung transplantation
Description: Evaluation and reconditioning of lungs following lung transplantation
Study: NCT04150926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black currant
Description: The effect of black currant puree will be compared with black currant-quinoa product, quinoa base and with liquid with glucose, fructose and sucrose~Experimental: Black currant and quinoa product~Active Comparator: Quinoa base Meal study comparing the effect of black currant puree with liquid with glucose, fructose and sucrose, black currant and quinoa product and quinoa base

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black currant-quinoa product
Description: The effect of black currant puree will be compared with black currant-quinoa product

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quinoa base
Description: The effect of black currant puree will be compared with quinoa base
Study: NCT00704717

Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031) pen
Description: PegIntron pen administered in accordance with approved labeling

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered in accordance with approved labeling.
Study: NCT04609865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Description: the lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours, and then 0.6mg/kg/h for 14 days or until extubation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
Study: NCT03533920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UNI-DEB
Description: Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
Study: NCT00491673

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uncemented primary bipolar hemiarthroplasty of the hip
Description: Uncemented primary bipolar hemiarthroplasty of the hip

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented primary bipolar hemiarthroplasty of the hip
Description: Cemented primary bipolar hemiarthroplasty of the hip
Study: NCT00640614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Description: Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Description: Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours.
Study: NCT04250519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite
Description: Sodium hypochlorite is used as intracanal irrigant to minimize the post operative pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hypochlorite
Description: Sodium hypochlorite is used as intracanal irrigant to minimize the post operative pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hypochlorite
Description: Sodium hypochlorite is used as intracanal irrigant to minimize the post operative pain
Study: NCT04387084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04250519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite
Description: Sodium hypochlorite is used as intracanal irrigant to minimize the post operative pain
Study: NCT03185247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Group-Based Treatment
Description: 10 week 90-minute weekly therapy sessions including both the adolescent and caregiver. Treatment will consist of psychoeducation about dysautonomia, motivational interviewing techniques to promote readiness for change, support around lifestyle and behavioral changes, core CBT components (e.g., relaxation training, linking thoughts, feelings, and behaviors, minimizing catastrophizing thoughts, cognitive coping, and exposure), and components of ACT aiming to increase cognitive flexibility (e.g., mindfulness, experiential avoidance, values, cognitive defusion, committed action), and relapse prevention and maintenance. Most sessions will involve homework assigned to the adolescent and their parent/legal guardian(s) to encourage practice at home.
Study: NCT02105831

Intervention type: OTHER
Intervention: Contrast ultrasound skeletal muscle perfusion imaging
Description: 1. Contrast ultrasound perfusion imaging will be performed in patients in whom LVAD will be placed for clinical indications of severe heart failure.
Study: NCT04336488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matrix Metalloproteinase Inhibitors (Orochem)
Description: topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenacort A,
Description: topical application of both drugs 3 times daily for 3 weeks as an active control
Study: NCT00553033

Intervention type: PROCEDURE
Intervention: Laparoscopic liver surgery
Description: Ultrasonic dissector, harmonic scalpel
Study: NCT04387084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-Term Fasting
Description: Undergo STF
Study: NCT00714857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
Study: NCT04368663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Japanese traditional medicine group
Description: TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Japanese traditional medicine group
Description: TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.
Study: NCT01656967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMBU Aura-I/aScope 2
Description: Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.
Study: NCT01472692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: 80mg PO daily for 8 weeks
Study: NCT01656967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Fastrach Single Use
Description: The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.
Study: NCT02390466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC-3S
Description: Administered via intra-muscular injection in the arm
Study: NCT04373161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Pulse Oximetry Monitoring
Description: Patients to check their home oxygen saturation three times daily and return to the ED for sustain oxygen \<92% or for worsening symptoms.
Study: NCT00005578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00795782

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic central lymph node dissection
Description: prophylactic ipsilateral versus bilateral central lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic central lymph node dissection
Description: prophylactic ipsilateral versus bilateral central lymph node dissection
Study: NCT01236053

Intervention type: DRUG
Intervention: Gabapentin prescriptions
Description: The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
Study: NCT04461652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic air-extraction catheter drainage
Description: This is a kind of venous catheter commonly used in clinic. It may bring less pain after being inserted into the chest, with an equivalent drainage effect with traditional thick drainage tube from our experience, especially in the aspect of gas drainage effect.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: prophylactic air-extraction catheter drainage
Description: This is a kind of venous catheter commonly used in clinic. It may bring less pain after being inserted into the chest, with an equivalent drainage effect with traditional thick drainage tube from our experience, especially in the aspect of gas drainage effect.
Study: NCT01094509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Tai Chi classes and exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided autobiography
Description: Autobiographical writing in class and at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong classes and exercises (exploratory)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Successful aging
Description: Seminar series on the theme of successful aging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination
Description: Combination of Tai Chi exercises and autobiographical writing

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparison
Description: No assigned behavioral activity (exploratory)
Study: NCT00309413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Cannabidiol
Description: 600 mg/day, oral, capsules, 2 weeks, than cross-over

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol/Placebo
Description: 600 mg/day, oral, capsules, 2 weeks, than cross-over
Study: NCT03439293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets.
Study: NCT00493181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-11 (IL-11 or Neumega)
Description: 10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.
Study: NCT03643406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Fatigue
Description: modified stroop task

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: documentary
Study: NCT04154566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: Aerobic exercise refers to exercise that involves or improves oxygen consumption by the body. It is the type of activity that uses large muscle groups. Its performance is in a continuous and rhythmic way with a main goal to make the heart and lungs work harder than they do when the person at rest
Study: NCT02991833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A New Incontinence Care Product
Description: The novel incontinent care product is dressed and removed removed by opening both sides. In the part surrounding the waist and thights of the novel incontinent care product flexibility is achieved by planting rubber bien. When developing new incontinence care products was taken counselling from a faculty member from Department of Textile Engineering of one University Faculty of Engineering. The insurance policies was prepared for each patients attended to the study (Number: 481360).New care product is put on the experimental group. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the novel incontinent care product was changed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaper
Description: In patients of the diaper group was used the optimum adult diaper (Pads, Linea TENA, SCA, Hygiene, Goteborg, Sweden) which was available in the market. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the diaper was changed.